 |
N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody |
|---|---|
| Trade Name | |
| Orphan Indication | Pancreatic Cancer |
| USA Market Approval | USA |
| USA Designation Date | 2000-12-07 00:00:00 |
| Sponsor | SmithKline Beecham Pharmaceuticals;1250 S. Collegeville Road;Collegeville, Pennsylvania, 19426 |
